Assessment of ER, PR and HER2 on cell blocks and core needle biopsies in metastatic breast cancer: a real-world experience.

IF 1.6 4区医学 Q3 PATHOLOGY

Acta Cytologica Pub Date : 2025-05-08 DOI:10.1159/000546274

Chen Lossos, Sandra Sanchez, Hiro Nonogaki, Edward Gabrielson, Ashley Cimino-Mathews, Zahra Maleki

{"title":"Assessment of ER, PR and HER2 on cell blocks and core needle biopsies in metastatic breast cancer: a real-world experience.","authors":"Chen Lossos, Sandra Sanchez, Hiro Nonogaki, Edward Gabrielson, Ashley Cimino-Mathews, Zahra Maleki","doi":"10.1159/000546274","DOIUrl":null,"url":null,"abstract":"Introduction: The status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) plays a crucial role in the management of patients with metastatic breast cancer. Herein we report our experience on ER, PR and HER2 immunostains on cell block and core needle biopsy (CNB) specimens of metastatic breast cancers.Methods: Cytological samples of metastatic breast cancer with associated cell blocks or core needle biopsies were identified on which ER, PR, or HER2 were ordered from 2019 to 2021. Both fine needle aspiration specimens and body effusion fluids were included. Patients' demographics, cancer histological subtype, biopsy site, specimen type (cell block or CNB) for immunohistochemistry and ER, PR and HER2 expression were recorded.Results: 192 specimens from 177 patients were identified. Patients' mean age was 58.5 years (range 24-96). The majority of samples were obtained from patients with invasive ductal carcinoma. Staining was performed on core biopsies (n=74/192, 38.5%) and on cell blocks (n=118/192, 61.5%). Pleural fluid (n=75) was the most commonly sampled site followed by the liver (n=48) and lymph nodes (n=44). ER, PR and HER2 were positive in 76.3%, 79.3% and 13.2% of samples, respectively. Concordantly, ER+PR+HER2- was the most common sample phenotype. Seven samples had insufficient tissue to evaluate ER, PR or HER2 status.Conclusion: ER, PR and HER2 immunohistochemical staining can be performed on cell block or CNB specimens of metastatic breast cancer and can provide reliable information to clinicians for optimal patient care. .","PeriodicalId":6959,"journal":{"name":"Acta Cytologica","volume":" ","pages":"1-18"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cytologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546274","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) plays a crucial role in the management of patients with metastatic breast cancer. Herein we report our experience on ER, PR and HER2 immunostains on cell block and core needle biopsy (CNB) specimens of metastatic breast cancers.

Methods: Cytological samples of metastatic breast cancer with associated cell blocks or core needle biopsies were identified on which ER, PR, or HER2 were ordered from 2019 to 2021. Both fine needle aspiration specimens and body effusion fluids were included. Patients' demographics, cancer histological subtype, biopsy site, specimen type (cell block or CNB) for immunohistochemistry and ER, PR and HER2 expression were recorded.

Results: 192 specimens from 177 patients were identified. Patients' mean age was 58.5 years (range 24-96). The majority of samples were obtained from patients with invasive ductal carcinoma. Staining was performed on core biopsies (n=74/192, 38.5%) and on cell blocks (n=118/192, 61.5%). Pleural fluid (n=75) was the most commonly sampled site followed by the liver (n=48) and lymph nodes (n=44). ER, PR and HER2 were positive in 76.3%, 79.3% and 13.2% of samples, respectively. Concordantly, ER+PR+HER2- was the most common sample phenotype. Seven samples had insufficient tissue to evaluate ER, PR or HER2 status.

Conclusion: ER, PR and HER2 immunohistochemical staining can be performed on cell block or CNB specimens of metastatic breast cancer and can provide reliable information to clinicians for optimal patient care. .

查看原文本刊更多论文

转移性乳腺癌细胞阻滞和核心穿刺活检中ER， PR和HER2的评估：真实世界的经验

雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2 （HER2）的水平在转移性乳腺癌患者的治疗中起着至关重要的作用。在此，我们报告了我们在转移性乳腺癌细胞块和核心针活检（CNB）标本上进行ER， PR和HER2免疫染色的经验。方法：对转移性乳腺癌细胞学样本进行鉴定，并进行相关细胞阻滞或核心穿刺活检，并在2019年至2021年期间对其进行ER、PR或HER2检测。细针抽吸标本和体液标本均包括在内。记录患者的人口统计学、肿瘤组织学亚型、活检部位、免疫组化标本类型（细胞块或CNB）以及ER、PR和HER2表达情况。结果：从177例患者中鉴定出192份标本。患者平均年龄为58.5岁（范围24-96岁）。大多数样本来自浸润性导管癌患者。对核心活检组织（n=74/192, 38.5%）和细胞块（n=118/192, 61.5%）进行染色。胸腔积液（n=75）是最常见的取样部位，其次是肝脏（n=48）和淋巴结（n=44）。ER、PR和HER2的阳性率分别为76.3%、79.3%和13.2%。同时，ER+PR+HER2-是最常见的样本表型。7个样本没有足够的组织来评估ER、PR或HER2状态。结论：ER、PR和HER2免疫组化染色可用于转移性乳腺癌细胞块或CNB标本，可为临床医生提供可靠的信息，以优化患者护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Cytologica 生物-病理学

CiteScore

3.70

自引率

11.10%

发文量

审稿时长

4-8 weeks

期刊介绍： With articles offering an excellent balance between clinical cytology and cytopathology, ''Acta Cytologica'' fosters the understanding of the pathogenetic mechanisms behind cytomorphology and thus facilitates the translation of frontline research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 national cytology societies around the world, ''Acta Cytologica'' evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlations. Original papers, review articles, meta-analyses, novel insights from clinical practice, and letters to the editor cover topics from diagnostic cytopathology, gynecologic and non-gynecologic cytopathology to fine needle aspiration, molecular techniques and their diagnostic applications. As the perfect reference for practical use, ''Acta Cytologica'' addresses a multidisciplinary audience practicing clinical cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine.